Wealthfront Advisers LLC Makes New $812,000 Investment in Zimmer Biomet Holdings, Inc. $ZBH

Wealthfront Advisers LLC purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, HoldingsChannel.com reports. The firm purchased 9,430 shares of the medical equipment provider’s stock, valued at approximately $812,000.

Other hedge funds also recently made changes to their positions in the company. DV Equities LLC purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at $25,000. Monetary Solutions Ltd purchased a new stake in Zimmer Biomet during the 4th quarter worth $30,000. Gen Wealth Partners Inc purchased a new stake in Zimmer Biomet during the 4th quarter worth $31,000. Elevation Wealth Partners LLC lifted its holdings in Zimmer Biomet by 145.9% in the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 229 shares in the last quarter. Finally, Cornerstone Financial Management LLC acquired a new position in Zimmer Biomet in the 4th quarter worth $37,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH opened at $101.01 on Friday. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The firm has a market cap of $19.27 billion, a price-to-earnings ratio of 24.58, a PEG ratio of 2.69 and a beta of 0.45. The stock has a 50 day moving average of $92.64 and a 200-day moving average of $91.00.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same period in the prior year, the company posted $2.07 EPS. The business’s revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.28% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Zacks Research lowered Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, July 27th. Citigroup reduced their price target on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a report on Thursday, May 28th. UBS Group restated a “buy” rating and set a $120.00 price objective on shares of Zimmer Biomet in a research note on Thursday, August 6th. Royal Bank Of Canada lifted their price objective on Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Finally, Citizens Jmp reduced their target price on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $104.42.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.